Therapeutics and Prophylaxis - HAN
Ruta de navegació
Jump To:
- August 2022: Starting August 15, 2022 Bebtelovimab will be commercially available for purchase, therefore no longer available through HPOP
- July 27, 2022: New Helpline and Ordering Pathway for Evusheld
- July 15, 2022: HHS Secretary Becerra renewed the COVID-19 Public Health Emergency Declaration for 90 days
- July 2022: Evusheld EUA: update on repeat dosing every 6 months
- July 2022: Bebtelovimab and Evushed EUA retain neutralization against all circulating variants
- July 6, 2022: FDA Authorizes Pharmacists to Prescribe Paxlovid
Overview of COVID-19 Therapeutics and Prophylaxis for Non-Hospitalized Patients
- Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
- Comparison table of treatment options.
- How providers may obtain these treatments or prophylaxis for their patients.
- Where providers can refer their patients for infusion therapies.
- Reporting requirements.
Treatment Guidelines:
NIH Therapeutic Management of Nonhospitalized Adults
The FDA has suspended distribution of sotrovimab due to the omicron BA.2 subvariant, which now accounts for more than half of COVID-19 infections. Bebtilovimab is now the preferred monoclonal antibody therapy.


Treatment

Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, bebtelovimab, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.
Prophylaxis
Description |
|
Patient Profiles |
|
UPDATE 02/24/2022: FDA announced a modification to the Emergency Use Authorization for Evusheld
Become a Provider
- Sign up with HPOP here.
- If you need help getting set up, email DPH.MABTherapy@illinois.gov
Locate Therapeutics and Prophylaxis In The City
- Infusion Providers Accepting External Referrals:
AMITA Health Saints Mary and Elizabeth Medical Center | Tel: 312-770-8534 Fax: 312-770-3182 |
John H Stroger Jr Hospital of Cook County | covidtherapeutics@cookcountyhhs.org |
Provident Hospital of Chicago | covidtherapeutics@cookcountyhhs.org |
Saint Anthony Hospital | ttruesdell@sahchicago.org |
Swedish Covenant Hospital | Tel: 773-907-7700 |
- Test to Treat in Chicago
- Providers who don’t want to receive allocations can use the ASPR COVID-19 Therapeutics Locator to find providers, pharmacies and infusion centers with doses on hand.
- For providers looking for immediate access to COVID-19 Therapeutics, available doses may be found on the IDPH Matchmaker Site. If you are a provider and have extra doses in between distribution cycles, please use this site so others have access.
State and Federal Reporting Requirements
- Report utilization and doses on hand of bebtelovimab, Evusheld, Paxlovid, and Legevrio twice per week by 11:59pm every Monday and Thursday.
- When reporting utilization of each product, report the quantity used since the last report. Do not report the cumulative amount over time.
- For any issues related to ordering or reporting of HPOP therapeutics, reach out to cars_helpdesk@cdc.gov or 833-748-1979
- Click here (https://aspr.hhs.gov/COVID-19/Therapeutics/Distribution/Pages/process-for-ordering.aspx) for more information on HPOP reporting.
Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
- Report utilization and doses on hand of bam/ete, sotrovimab, REGEN-COV weekly by 11:59pm every Wednesday
Reporting into NHSN for Long Term Care Facilities
- Report ALL therapeutics utilization into the Resident Therapeutics Form of the COVID-19 Module.
- Instructions for Completion (https://www.cdc.gov/nhsn/pdfs/covid19/ltcf/57.158-toi-508.pdf)

Provider Resource Library and Other Useful Links
- Guidelines for Product Return: Bamlanivimab, BAM/ETE, REGEN-COV, Sotrovimab
- NIH Paxlovid Checklist Tool for Prescribers
- FDA Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers
- COVID-19 Therapeutics
- Paxlovid Drug interactions
- COVID-19 Drug Interactions Checker App
- Illinois Department of Public Health Therapeutics
- CDC COCA Call: What Clinicians Need to Know About the New Antiviral Medications For COVID-19
- CDC/IDSA Clinician Call: COVID-19 Treatment Updates Plus the Latest on Omicron
- Cook County Health Systems Webinar on Outpatient COVID-19 Treatment for High Risk Populations
- CDC MMWR: Hospitalization and ED Encounters for COVID-19 After Paxlovid Treatment
Shelf life Extensions
CHI COVID rX
Pursuant to Health Order No. 2020-4 sites administering USG-Purchased COVID-19 therapeutics in the City of Chicago must report individual-level utilization data.
Click here to visit the portal and share your data with us.
For questions about reporting or data requirements, please the view the FAQ or contact Frances Frances Lendacki Frances Lendacki at Frances Lendacki @cityofchicago..org or questions related to medication allocations andaccess, please contact Illinois Department of Public Health at (DPH.MABTherapy@illinois.gov)
Sites interested in providing USG-purchased COVID-19 therapeutics, sign up for the Heath Partners Ordering Portal here.